TCA
RMD icon

Trifecta Capital Advisors’s ResMed RMD Stock Holding History

Trifecta Capital Advisors’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195 Buy
+1
New +$207 ﹤0.01% 465
2025
Q4 		– Sell
-7
Closed -$1.92K – 412
2025
Q3 		$1.92K Hold
7
– – ﹤0.01% 340
2025
Q2 		$1.81K Hold
7
– – ﹤0.01% 350
2025
Q1 		$1.57K Hold
7
– – ﹤0.01% 333
2024
Q4 		$1.6K Hold
7
– – ﹤0.01% 328
2024
Q3 		$1.71K Hold
7
– – ﹤0.01% 329
2024
Q2 		$1.34K Hold
7
– – ﹤0.01% 353
2024
Q1 		$1.39K Hold
7
– – ﹤0.01% 344
2023
Q4 		$1.21K Buy
+7
New +$1.08K ﹤0.01% 381

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Trifecta Capital Advisors's RMD Position: Q2 2026 in Review

Trifecta Capital Advisors opened a new position in ResMed (RMD) in Q2 2026: 1 share worth $195. The stake represents ﹤0.01% of the portfolio and ranks #465 among its holdings. This is a return to the name: Trifecta Capital Advisors previously reported a position in RMD as recently as Q3 2025.

Trifecta Capital Advisors first reported a position in RMD in Q4 2023 and has held it in 9 quarters since. The position peaked at $1.92K in Q3 2025. 889 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Trifecta Capital Advisors held 1 share of ResMed worth $195 as of Q2 2026.
  • ResMed was a new Trifecta Capital Advisors position in Q2 2026.
  • ResMed made up ﹤0.01% of Trifecta Capital Advisors's portfolio in Q2 2026, its #465 holding.
  • Trifecta Capital Advisors first reported a position in ResMed in Q4 2023 and has held it in 9 quarters since.
  • Trifecta Capital Advisors's ResMed position peaked at $1.92K in Q3 2025.
  • 889 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Trifecta Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.